| pubmed-article:4065175 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:4065175 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:4065175 | lifeskim:mentions | umls-concept:C0039950 | lld:lifeskim |
| pubmed-article:4065175 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:4065175 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:4065175 | lifeskim:mentions | umls-concept:C1298613 | lld:lifeskim |
| pubmed-article:4065175 | lifeskim:mentions | umls-concept:C0599918 | lld:lifeskim |
| pubmed-article:4065175 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:4065175 | pubmed:dateCreated | 1986-1-16 | lld:pubmed |
| pubmed-article:4065175 | pubmed:abstractText | Sodium thiosulfate has been shown experimentally to protect against cisplatin-induced renal insufficiency by inactivating the nephrotoxic as well as cytotoxic properties of the agent. However, significant plasma levels of 'active' cisplatin have been demonstrated following high-dose intracavitary cisplatin administration with simultaneous intravenous thiosulfate delivery. At the UCSD Cancer Center 131 patients have been treated with a total of 485 courses (median per patient, 3; range 1-18) of intrapleural or intraperitoneal cisplatin with intravenous thiosulfate protection. Seventy-six patients (58%) had previously been treated with intravenous cisplatin. A total of 14 courses (2.9%) of intracavitary therapy were complicated by a serum creatinine rise to greater than 1.5 mg% which, in all but three cases, returned to the normal range within 1 month following treatment. All but one patient demonstrating clinical evidence of nephrotoxicity had been heavily pretreated with cisplatin. We conclude that thiosulfate can protect against clinically significant cisplatin-induced nephrotoxicity by cisplatin delivered in high doses via the intracavitary route. | lld:pubmed |
| pubmed-article:4065175 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:language | eng | lld:pubmed |
| pubmed-article:4065175 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:4065175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4065175 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:4065175 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:4065175 | pubmed:issn | 0277-5379 | lld:pubmed |
| pubmed-article:4065175 | pubmed:author | pubmed-author:HowellS BSB | lld:pubmed |
| pubmed-article:4065175 | pubmed:author | pubmed-author:MarkmanMM | lld:pubmed |
| pubmed-article:4065175 | pubmed:author | pubmed-author:ClearySS | lld:pubmed |
| pubmed-article:4065175 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:4065175 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:4065175 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:4065175 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:4065175 | pubmed:pagination | 1015-8 | lld:pubmed |
| pubmed-article:4065175 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:meshHeading | pubmed-meshheading:4065175-... | lld:pubmed |
| pubmed-article:4065175 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:4065175 | pubmed:articleTitle | Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. | lld:pubmed |
| pubmed-article:4065175 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:4065175 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:4065175 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:4065175 | lld:pubmed |
